If Freenome Holdings Inc.’s $254 million funding round is a sign, the capital markets for med-tech may finally be thawing. The cancer diagnostics company’s latest cash infusion brings its total funds raised to date to more than $1.3 billion. Freenome co-founder and Chief Product Officer Riley Ennis told BioWorld the company’s success in raising cash in a challenging market was attributable to the “perfect storm of huge unmet need and the opportunity that we have, given the treatment advancements.”
/PRNewswire/ The "Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path.
In-Depth Analysis of Next Generation Sequencing (NGS) Tests, 2023 Clinical Pipeline Report lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Oncimmune Holdings PLC on Wednesday said it appointed Martin Gouldstone as its new chief executive, replacing Adam Hill who stepped down following the divestment of Oncimmune Ltd.
Chief Financial.
/PRNewswire/ Freenome, a privately held biotech company, will present research at the American Association for Cancer Research (AACR) Annual Meeting that.